Title:Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia
VOLUME: 20 ISSUE: 3
Author(s):Barbara Ziemba, Hanna Sikorska, Magdalena Jander, Wojciech Kuncman, Marian Danilewicz, Dietmar Appelhans, Maria Bryszewska, Maciej Borowiec and Ida Franiak-Pietryga*
Affiliation:GeneaMed LTD, Lodz, Bio-Assistance, Montreal, QC, GeneaMed LTD, Lodz, Department of Pathomorphology, Medical University of Lodz, Lodz, Department of Pathomorphology, Medical University of Lodz, Lodz, Leibniz Institute of Polymer Research Dresden, Dresden, Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Department of Clinical and Laboratory Genetics, Medical University of Lodz, Lodz, GeneaMed LTD, Lodz
Keywords:Poly(propylene imine), dendrimer, tumour, chronic lymphocytic leukaemia, anticancer therapy, in vivo, ex vivo.
Abstract:Background: Chronic Lymphocytic Leukaemia (CLL) is an indolent disorder, which mainly affects
older adults. Since the advent of chemoimmunotherapy, great progress has been made in its treatment. However,
some patients develop a more aggressive form of the disease and are included in the group of high-risk CLL
patients with a dismal prognosis and a need for new therapies.
Objective: Maltotriose-modified poly(propylene imine) dendrimers were presented as potential agents in targeted
therapy for CLL in the murine xenograft model.
Methods: Tumour, brain and internal organs resected from NOD scid gamma mice were subjected to gross and
histopathological evaluation.
Results: The results of ex vivo tissue examination indicated that open-shell glycodendrimers prevented/inhibited
the spread of CLL into the brain and internal organs and its transformation into a more aggressive form.
Conclusion: The results of the study have a potentially important impact on the design of future personalized
therapies as well as clinical trials.